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Contrast-Induced Nephropathy
Ahmed Shawky Elserafy and Tarek Abdelsalam
Abstract
With the worldwide increase in the incidence of atherosclerotic coronary artery 
disease, the rate of coronary interventions has increased. One of the serious compli-
cations of this procedure is contrast-induced nephropathy (CIN). This complication 
can lead to poor outcomes, with an increase in morbidity and mortality of patients. 
The pathophysiology and risk factors for the occurrence of contrast-induced 
nephropathy are several and interconnected. The most proposed management of 
this entity is prophylaxis and thus avoidance of its occurrence. We will take a deeper 
look on the pathophysiology, the mechanisms by which this complication is aggra-
vated, and how to expect and manage such a problem.
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1. Introduction
Contrast-induced nephropathy (CIN) is a grave complication of angiographic 
procedures and arises from administration of iodinated contrast media (CM) 
[1]. CIN is the third most common cause of hospital acquired acute renal injury 
representing about 12% of the cases. The incidence of CIN varies from 0 to 24% 
depending on the patient’s risk factors [2]. It is generally a transient and reversible 
state of acute renal failure [3]. However, the development of CIN is linked to a more 
prolonged hospital stay, an increased morbidity and mortality, and a high health-
care cost. Treatment of CIN is predominantly of supportive nature, consisting of 
calculated fluid and electrolyte management; however, dialysis may be required in 
some cases [3].
2. Definition
Clinical and experimental studies have used different laboratory parameters 
to define CIN [4, 5]. Currently, CIN is most commonly defined when either of the 
following occur within 48 h after contrast administration and persisting for 2–5 
days [6, 7]:
• A 25% increase in serum creatinine (SCr) concentration from baseline value
• An absolute increase in SCr of at least 0.5 mg/dL (44.2 μmol/L)
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3. Epidemiology
CIN is one of the most significant causes of hospital-acquired acute kidney 
injury (AKI) [8] and presents about 12% of the cases [9]. It represents the third 
most common cause after renal hypoperfusion (42%) and postoperative renal 
injury (18%). The reported incidence of CIN following percutaneous coronary 
intervention (PCI) lies between 0 and 24%. This depends on the associated risk 
factors, with the greatest incidence being reported after emergency PCI [10, 11]. 
A meta-analysis which included 40 studies showed a 6% incidence of CIN follow-
ing contrast-enhanced computed tomography (CT) [12], 9% following peripheral 
angiography [3], and 4% following intravenous pyelography [13]. The incidence 
of CIN is low in patients with normal renal function (0–5%) [14]. However, there 
is an incidence of 12–27% in patients having preexisting renal impairment [15]. 
Moreover, in one study, an incidence as high as 50% was found in patients with dia-
betic nephropathy undergoing coronary angiography despite the use of low-osmolar 
CM (LOCM) and adequate hydration. Also, up to 15% of them needed dialysis [16]. 
Development of CIN is associated with a longer duration of hospital stay and an 
increased morbidity and mortality, in addition to more costs [1, 17]. Elevation of 
post-PCI serum creatinine may have prognostic significance regardless of the initial 
kidney functions. In fact, a slight elevation in serum creatinine (25–35 μmol/l) is 
associated with an increase in 30-day mortality [18]. Furthermore, post-PCI serum 
creatinine elevation has been reported to be linked to higher 1-year mortality than 
periprocedural myocardial necrosis [19].
4. Risk factors
Mild, transient decreases in GFR occur after contrast administration in nearly all 
patients. The development of clinically significant acute renal failure depends very 
much upon the presence or absence of certain risk factors (Table 1); factors that 
increase the incidence of development of CIN are linked to the patient’s comorbid 
conditions, the procedure to be performed, and the nature of the contrast agents [21].
4.1 Preexisting renal disease
Preexisting renal disease with an elevated basal level of serum creatinine is 
the most important risk factor for the occurrence of CIN. The incidence of CIN in 
patients with preexisting chronic kidney disease is extremely high, ranging from 
Degree of 
risk
Nonmodifiable risk 
factors
Modifiable risk factors
Major Preexisting renal disease
Diabetes mellitus
Osmolality and ionic content of contrast medium
Volume of contrast medium administered
Repeated exposure to contrast medium
Minor Age
Gender
Reduced ejection fraction
Congestive heart failure
Hypertension
Dehydration
Myocardial infarction less than 24 h before angiography
Circulatory collapse
Anemia
Table 1. 
Common risk factors for contrast nephropathy after coronary angiography [20].
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14.8 to 55% [20]. As depicted in a study, despite pre-procedure adequate hydra-
tion and the use of nonionic CM, CIN happened in one-third of the 439 patients 
who underwent PCI and had basal creatinine level more than or equal to 1.8 mg/dl 
[22]. The higher the basal serum creatinine level, the greater the risk of developing 
CIN. As seen in a study, if basal serum creatinine level is estimated to be ≤1.2 mg/dl, 
the risk of development of CIN is just 2% [23]. In patients with values of creatinine 
in the range of 1.4–1.9 mg/dl, the risk of CIN in comparison with that in the previous 
group increases fivefold (10.4%) [23]. Regarding patients with baseline serum cre-
atinine more than or equal to 2.0 mg/dl, 62% of them developed CIN [24]. However, 
baseline creatinine is not reliable enough for the determination of patients who are 
at risk for CIN. This arises due to the variation on the basis of gender, age, and mus-
cular mass. For instance, a normal serum creatinine value probably correlates with 
a moderate decrease in renal function. In order to properly evaluate renal function, 
assessment of creatinine clearance should be done. The direct measurement of the 
creatinine clearance is not practical to be done; however, its estimation based on the 
Cockcroft-Gault formula or Modification of Diet in Renal Disease equation can be 
easily performed. Multiple studies have proven that an estimated glomerular filtra-
tion rate (eGFR) of 60 mL/min/1.73 m2 is a cutoff value for considering patients at 
high risk for the development of CIN. Thus, the estimation of GFR is crucial for CIN 
risk assessment [25].
4.2 Diabetes mellitus
Diabetic patients represent a very important proportion of those undergo-
ing contrast exposures due not only to the prevalence of diabetes in the general 
population but also the ability of the disease to cause a wide spectrum of diseases 
which require radiological procedures using contrast media. The incidence of CIN 
in diabetic patients varies from 5.7 to 29.4% [26]. Importantly, in diabetic patients 
with preserved renal function and without other risk factors, the rates of CIN are 
approximately equal to those of a nondiabetic population [27], while clinically 
important CIN mostly happens in a group of diabetics with preexisting renal 
impairment [27].
4.3 Age
Several studies showed that older age is an independent predictor of CIN [28]. 
The reasons for higher risk are multifactorial, which encompasses age-related 
changes in renal function including decreased glomerular filtration rate, renal 
concentration ability, and tubular secretion. The presence of multi-vessel coronary 
artery disease, mandating complex more prolonged PCI, combined with more dif-
ficult vascular access that results from tortuosity and calcification of the vessels that 
frequently requires a greater amount of contrast, and therefore represent additional 
factors of elevated CIN risk in elderly.
4.4 Gender
Ovarian hormones can have an influence upon the renin-angiotensin system 
as well as the renal blood flow. In a retrospective study of 8628 patients who 
underwent PCI, female sex presented an independent risk predictor of CIN (OR = 
1.4, p < 0.0001). One-year analyses of outcomes by gender demonstrated a higher 
mortality rate when compared to males in a cohort of CIN patients (14 vs 10%, p = 
0.05) [29].
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4.5 Heart failure
Advanced congestive heart failure (New York Heart Association class III or IV), 
reduced left ventricular ejection fraction, or any history of congestive heart failure 
are independent predictors of CIN and contribute to a greater risk in patients who 
have diabetes or renal disease. The risk arises as a result of decreased renal blood 
flow due to low cardiac output in those patients. Moreover, the risk is enhanced by 
this population’s use of specific medications such as aspirin, diuretics, and angio-
tensin converting enzyme (ACE) inhibitors [30].
4.6 Anemia
Anemia can cause deterioration of renal ischemia which can be an acceptable 
explanation for the higher incidence of contrast-induced nephropathy in patients 
with a lower hematocrit level. A baseline hematocrit value of less than 39% for men 
and less than 36% for women is considered a risk that leads to a higher incidence 
of CIN. This relation was investigated in a prospective study of 6773 patients who 
underwent PCI [31]. A lower basal hematocrit value was an independent risk 
predictor of CIN; and every 3% decline in basal hematocrit resulted in a significant 
increase in the occurrence of CIN in patients with and without chronic kidney 
disease (11 and 23%, respectively). Dangas et al. showed that the basal hematocrit 
level is an independent risk factor for the occurrence of CIN among patients with 
chronic kidney disease (OR = 0.95, p < 0.00001) [17].
4.7 Hyperuricemia
Contrast media have a uricosuric effect, which is caused by increased renal 
tubular secretion of uric acid. Moreover, hyperuricemia is accompanied by an acti-
vated renin-angiotensin-aldosterone system, enhanced synthesis of reactive oxygen 
species, increased endothelin-1, tubular obstruction by uric acid, and an inhibited 
nitric oxide synthesis that provokes the development of CIN [32].
4.8 Hypercholesterolemia
Altered nitric oxide-dependent renal vasodilatation is common in hypercho-
lesterolemia. Hypercholesterolemia enhanced the occurrence of CIN through the 
reduced production of nitric oxide [24].
4.9 Hypovolemia
Hypovolemia leads to active sodium reabsorption, which is an oxygen-depen-
dent process, and increases neurohumoral vasoconstrictive stimuli that can dimin-
ish medullary oxygenation. The toxic actions of contrast media on the renal tubular 
lumen can be exaggerated in hypovolemia. Decreased circulatory volume and renal 
perfusion augment vasoconstriction of renal vasculature after administration of 
CM. Volume expansion decreases the activity of the renin-angiotensin system, 
increases the perfusion of the medulla, and minimizes the elevation in blood viscos-
ity and osmolality. Currently, the most effective preventive measure against the 
development of CIN is proper hydration [33].
4.10 Hypertension
The alteration in intrarenal expression of vasoactive mediators, mainly renin-
angiotensin system and nitric oxide, is a common cause that ranks hypertension as 
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an important risk factor for CIN. Impaired nitric oxide-dependent renal vasodi-
latation is common in individuals who are hypertensive. In addition, a decreased 
nephron count could predispose hypertensive patients to CIN.
4.11 Nephrotoxic drugs
Nephrotoxic drugs that inhibit the vasodilatory effects of prostaglandins 
make the kidneys extremely vulnerable to the toxic effect of contrast media. 
Aminoglycosides, sulfonamides, and their combinations with furosemide are very 
risky. Cyclosporin A may intensify medullary hypoxia, and cisplatin can bind 
to sulfhydryl groups. Mannitol can increase the metabolic load and the oxygen 
consumption of the kidney, and amphotericin B can cause the combined effect of 
mannitol and cyclosporine A. It has been demonstrated that nonselective NSAIDs 
and selective COX-2 inhibitors decrease the availability of vasodilatory prostaglan-
dins in the kidneys and enhance the vasoconstrictive effect of CM [34].
4.12 ACE inhibitors and angiotensin receptor blockers
ACE inhibitors have been identified as a risk factor for CIN because of their 
ability to reduce renal function. On the contrary, some small studies have shown 
that the inhibition of angiotensin II can decrease renal vasoconstriction follow-
ing the injection of contrast media. In a randomized controlled study including 
71 patients with diabetes who underwent coronary angiography and randomized 
to captopril (25 mg thrice daily) or control, there was a significant decrease in 
CIN in the patients who received captopril compared with the control group (6 vs 
29%, respectively, p < 0.02) [35]. A randomized controlled study was performed 
on 80 patients with serum creatinine less than 2 mg/dl who underwent coronary 
angiography where captopril was administered in 48 patients preceding coronary 
angiography. CIN occurred in five patients (10.4%) in the captopril group, com-
pared with only one patient (3.1%) in the control group (p = 0.02) [36]. We can 
say that holding ACE inhibitor or ARB use before coronary angiography is to be 
considered.
4.13 Acute myocardial infarction
A study by Rihal and his colleagues pointed that acute myocardial infarction 
occurring within 24 h before administration of the CM is a risk predictor to CIN 
(OR = 1.85, p = 0.0006). This study showed that CIN represents a frequent com-
plication in acute myocardial infarction. This can occur, as well, in patients with a 
normal baseline renal function [30]. In 2082 percutaneous interventions for acute 
myocardial infarction, a more than sevenfold (3.2 vs 23.3%) elevation in 1-year 
mortality in patients who acquired CIN was acknowledged [37].
4.14 Contrast medium-related risk factors
4.14.1 Increased dose of contrast medium
Based upon multiple sources, the relatively unhazardous cutoff point of contrast 
amount ranges from 70 mL up to 220 mL. However, very small doses as much as 
20–30 mL are capable of inducing CIN. In a study that included patients performing 
coro¬nary angiography, each 100 mL of contrast medium administered was linked 
to a significant increase of 12% in the risk of CIN (OR = 1.12, p = 0.02) [32]. A clear 
accepted dose is four times the creatinine clearance.
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4.14.2 High-osmolar and ionic CM
Most side effects attributable to contrast media are linked to its hypertonicity. 
Currently, four main types of contrast media are used in practice today, includ-
ing nonionic low-osmolar, ionic low-osmolar, nonionic iso-osmolar, and ionic 
high-osmolar contrast media. In a large study which compared the nonionic low-
osmolality agent iohexol to the ionic high-osmolality agent meglumine/sodium 
diatrizoate in patients with preexisting renal impairment undergoing angiography, 
patients with renal impairment who received diatrizoate were 3.3 times more liable 
to develop CIN in comparison with those receiving iohexol [38]. NEPHRIC trial 
is a randomized, prospective study that made a comparison between the nonionic 
iso-osmolar CM iodixanol with the nonionic low-osmolar CM iohexol in 129 
patients with renal impairment and diabetes undergoing coronary or aortofemoral 
angiography. The incidence of CIN was 3% in the iodixanol group and 26% in the 
iohexol group (p = 0.002) [39]. In one other randomized study, the incidence of 
CIN provoked by iodixanol and iohexol was compared in 124 patients with basal 
creatinine level >1.7 mg/dl. The incidence of CIN was 3.7% in iodixanol group and 
10% in iohexol group (p > 0.05) [17]. In addition, CM are classified as ionic and 
nonionic. A randomized trial of 1196 patients performing coronary angiography 
showed that nonionic CM lowered the incidence of CIN in patients with preexisting 
renal impairment [38]. In high-risk patients, it is better to avoid the use the high-
osmolar and ionic CM to lower the risk of CIN.
5. Pathophysiology
No definitive causative has been defined as regards the pathogenesis of CIN 
in the literature. The most accepted theory for the development of CIN following 
contrast administration relies upon the vasoconstriction of the vessels in the renal 
medulla leading to reduced oxygen delivery [40]. Reduced oxygen delivery and 
prolonged vasoconstriction leads to enhanced production of oxygen-free radicals 
like hydrogen peroxide and superoxide leading to increased damage [41]. Other 
suggested causes of this condition are elevated blood viscosity, reperfusion injury, 
direct toxic damage to the cells, and the release of dopamine, angiotensin II, and 
vasopressin. These factors induce further vasoconstriction and damage the renal 
function [42]. The use of supportive therapy in critically ill patients, for instance, 
the mechanical ventilation and inotropic drugs, and the variable health risks this 
group of patients have as anemia and sepsis have been shown to increase additional 
kidney damage resulting from vasoconstriction and hypoxia [43].
5.1 Regional hypoxia as a cause of contrast-induced nephropathy (CIN)
Renal perfusion is very high in the cortex. The medullary portions are main-
tained at the border of hypoxia such that pO2 levels can be as low as 20 mmHg 
[44]. This is the price for maintaining the countercurrent mechanism used for the 
control of urine excretion. A vulnerable kidney region is the deeper part of the 
outer medulla, an area far from the vasa recta which supply the renal medulla with 
blood. It is there where the thick ascending limbs of the loop of Henle encounter 
hypoxic damage [45]. The cause for the vulnerability of the outer medullary 
portion of the nephron is the relatively higher oxygen needs due to salt reabsorp-
tion. The addition of contrast media to the medium augments the hypoxic injury 
imposed upon this region by increasing the renal vascular resistance, as seen in 
the rat model [46]. A second factor that has been postulated to mediate CIN is 
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an elevated oxygen demand due to an enhanced workload in the tubular cells. 
First, there is a temporary increase in GFR that follows giving contrast media 
[47], and second, osmotic diuresis may reduce the para-cellular absorption of 
the proximal tubular cells, causing a greater load of NaCl that has to be absorbed 
in the distal tubules. Liss et al. [48] have shown that contrast media can enhance 
medullary blood flow to the kidney, although pO2 decreases, which is supported 
also by a study of Heyman et al. [49]. These two studies suggest that an increased 
oxygen demand has taken place following contrast media injection. Local kidney 
hypoxia can be augmented by the systemic effects of some contrast media, such as 
transiently diminished cardiac output [50] and abnormal pulmonary ventilation-
perfusion relationship [51]. Also, the amount of oxygen delivered to the peripheral 
tissues might be impaired, since contrast media can increase oxygen affinity of 
hemoglobin [52]. If renal outer medullary hypoxia causes CIN, the blockade of the 
transporters in this portion of the nephron must have helpful effects on its preven-
tion. The major part of the transport that occurs in the medullary thick ascending 
limb is the Na-K+-2Cl− cotransporter, which, as mentioned above, is blocked by 
furosemide. Blocking this transport would significantly decrease the local oxygen 
consumption.
5.2 Radiocontrast-mediated changes in renal blood supply
Renal blood flow and intrarenal microcirculation are markedly altered by 
contrast medium (CM) [53]. The extent and distribution of renal hemodynamic 
changes depends on the species investigated as well as on the type, volume, and 
rate of contrast administration. Moreover, renal hemodynamic effects of CM 
gravely depend on the hydration state and on additional predisposing factors that 
may have an effect on the renal circulation and the tone of the renal vasculature, 
such as chronic renal disease, diabetes mellitus, senility, and inflammation. In an 
early study in dogs subjected to a high-osmolar CM, total renal blood flow was 
transiently enhanced for 5–15 min, followed by a decline by 25% below baseline, 
reaching beyond a couple of hours [54]. In healthy humans, renal blood flow fell 
8% over 30 min after the intravenous administration of conventional doses of CM 
[53]. On the contrary, in patients with chronic kidney disease undergoing coronary 
angiography, a transient short augmentation of renal blood flow was followed by a 
dramatic 40% decline, lasting for more than 3 h [54].
5.3 Cytotoxic effects on renal tubular cells
Investigations performed in vitro on cell lines are used to assess the renal tubular 
cell function or damage. A porcine cell line of renal proximal tubules, LLC-PK1, 
was used by Hardiek et al. [55] to investigate the occurrence of CIN. An effect on 
apoptosis was not elucidated, even though proliferation was impaired. Diminished 
proliferation will have a hazardous effect on renal function with a delay of hours 
to days, which may help in explaining the course of CIN. Independent of the 
contrast media used, tubular cell damage can occur. A more specific distortion of 
proximal tubular function seems to be a perturbation of mitochondrial enzymatic 
activity and mitochondrial membrane potential [56]. The degree of mitochondrial 
enzymatic activity impairment depends mainly on two features of the contrast 
media: the ionic nature as well as the molecular structure. Remarkably, low-osmolar 
contrast media had the least observed effects, followed by the iso-osmolar contrast 
media. Ionic compounds showed the most deleterious effects [56]. In the distal 
tubule, contrast media may trigger apoptotic effects in the cells, as depicted in the 
Madin-Darby canine kidney (MDCK) cell line model [57].
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5.4 Generation of oxygen-free radicals
Among the often-discussed mechanisms, superoxide and other reactive oxygen 
species (ROS) have been discussed to be an aggravating factor for CIN. Oxygen free 
radicals are endogenously produced, and levels can increase during oxidative stress. 
The commonest oxygen radicals are superoxide (O2
−), hydrogen peroxide (H2O2), 
and hydroxyl radical (OH−) [58]. O2
− and OH− are more reactive in comparison 
with H2O2, which is not a radical but shows greater membrane permeability. O2
− 
rapidly scavenges nitric oxide (NO) and could diminish NO activity in the renal 
vessels. Since NO decreases oxygen consumption, it is considerable to speculate 
that decreased (scavenged) NO levels in diabetes increases oxygen consumption, 
thus leading to reduced partial oxygen pressure values with consequences for 
endothelial-epithelial structure and function. ROS can play a role in the effects 
of various vasoconstrictors that are considered necessary for the development of 
CIN. Because ROS are extracellular signaling molecules, they can have a crucial role 
in mediating the effects of vasoconstrictors, such as thromboxane A2, angiotensin 
II, adenosine, endothelin (ET)-1, and norepinephrine. The adverse effects of CM 
on kidney function can therefore involve the generation of ROS, for example, via 
adenosine formation. This idea is supported by experiments in which the  generation 
of ROS was inhibited by allopurinol or the amount of ROS was decreased by O2
− 
dismutase. In these models, CM-induced reductions in glomerular filtration rate are 
attenuated [59].
6. Preventive measures against contrast-induced nephropathy
6.1 Adequate hydration
6.1.1 Intravenous hydration
Adequate hydration for patients performing CM-enhanced imaging studies was 
suggested approximately 40 years ago [30]. The beneficial effects of hydration were 
initially reported in the early 1980s by studies that compared outcomes of hydrated 
patients with historical controls [60, 61]. These reports were supported by the first 
RCT in 1994, concluding that patients with chronic renal impairment benefit better 
from intravenous (0.45%) saline administration (for 12 h before and 12 h after 
angiography) in comparison with saline plus mannitol or furosemide [62]. Since 
then, multiple RCTs have assured the benefit of intravenous normal saline (0.9%) 
hydration that is started 12 h preceding to 12 h after CM injection [63–65] in the 
prevention against CIN over 0.45% saline [65] or a fluid bolus (300 mL) during CM 
administration only [66]. The rate of infusion was reported as 1 mL/kg/h [67]. CM 
safety committee endorse a regime of intravenous infusion of 1.0–1.5 mL/kg/h for at 
least 6 h before and after CM administration [68].
6.1.2 Oral hydration
In order to overcome the limitations of outpatient intravenous hydration, inves-
tigators have assessed the use of pre-procedure oral hydration followed by post-
procedure intravenous hydration in patients who are admitted for catheterization 
on the day of procedure. In an RCT on patients with mild-to-moderate renal insuf-
ficiency, Taylor et al. reported an effective protocol which includes pre-angiography 
oral hydration (1000 mL clear fluids over 10 h) that is followed by 6 h of intravenous 
hydration (0.45% normal saline solution at 300 mL/h) that starts just before CM 
9Contrast-Induced Nephropathy
DOI: http://dx.doi.org/10.5772/intechopen.90457
exposure [69]. The results were comparative with overnight intravenous hydration 
(0.45% normal saline solution at 75 mL/h for both 12 h before and after angiogra-
phy). A limitation of this protocol can be high infusion rate (300 mL/h) post-proce-
dure for the patients having left ventricular impairment. Trivedi and his colleagues 
demonstrated different results as they observed that patients with unrestricted oral 
hydration had more opportunities of acute renal impairment compared to those 
receiving normal saline for 24 h (at a rate of 1 mL/kg/h) beginning 12 h before the 
scheduled catheterization (p = 0.005) [68]. In this study, however, there was no set 
protocol for oral hydration for patients to follow that probably could have contrib-
uted to its ineffectiveness. Later, Dussol et al. randomized 312 patients with chronic 
kidney disease (CKD) to receive either per oral sodium chloride (NaCl) (dose: 
1 g/10 kg bodyweight/day for 2 days before the procedure), intravenous normal 
saline 15 mL/kg for the 6 h preceding the procedure (control arm), theophylline, or 
furosemide in addition to the treatment given to patients in the control arm [70]. 
Oral saline hydration was found to have comparative effectiveness as intravenous 
saline hydration as regards preventing CI-AKI.
6.1.3 Sodium bicarbonate-based hydration
The acidic PH promotes free radical production (which is found in tubular 
urine) [71], while elevated pH of normal extracellular fluid inhibits it [72, 73]. 
Since CM administration escalates the oxidative stress and increases the generation 
of free radicals and reactive oxygen species (ROS), alkalinizing renal tubular fluid 
with bicarbonate appears to be a logical strategy to protect against renal injury 
[74]. As a result of active reabsorption, bicarbonate concentration in the renal 
tubules lowers (to about 6 mEq/L), and the tubular fluid pH is approximately 6.5 
near the end of the proximal tubule in the renal medulla [75]. In the descending 
loop of Henle, water and chloride are passively reabsorbed. This elevates urine pH 
to ~7.4 at the tip of the papilla, and this part is spared from contrast nephropathy 
[76], which suggests that higher pH is protective. Also important is the observation 
that outer medulla is the most susceptible to CIN [62] and has acidic pH [72] that 
promotes activity of ROS. Superoxide, a ROS generated by ischemia, might react 
with medullary NO to produce the potent oxidant peroxynitrite [73]. At physiologic 
concentrations, bicarbonate scavenges peroxynitrite and other ROSs produced from 
NO [74]. Thus, several oxidant mechanisms of renal injury might be avoided using 
sodium bicarbonate. The useful effect of higher proximal tubular pH is approved by 
a report that acetazolamide, a carbonic-anhydrase inhibitor which blocks proximal 
tubular bicarbonate reabsorption, is protective in contrast-induced renal failure 
[77]. Merten et al. reported first study on the use of sodium bicarbonate in humans 
as a nephron-protective agent [78]. Patients received 154 mEq/l of either NaCl (in 
5% dextrose H2O) or sodium bicarbonate (in dextrose H2O), as a bolus of 3 mL/kg/h 
for 1 h before iopamidol contrast, followed by an infusion of 1 mL/kg/h for 6 h after 
the procedure. CIN occurred in 8 patients (13.6%) infused with NaCl but in only 1 
(1.7%) of those receiving sodium bicarbonate (p = 0.02). Afterwards, many RCTs 
have compared the efficacy of sodium bicarbonate with saline hydration regarding 
the prophylaxis against CIN. These have been reviewed in multiple meta-analysis 
[79–82], which concluded that sodium bicarbonate-based saline hydration is more 
efficacious to saline hydration only.
6.1.4 Pharmacological prophylaxis
Various drugs have been assessed as prophylactic nephroprotective agents 
against contrast-induced acute kidney injury (CI-AKI) such as N-acetylcysteine 
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(NAC) [36, 83], statins [84, 85], ascorbic acid [76, 86], and theophylline [87]. 
However, only statins have been approved for the prevention against the occur-
rence of CIN. Currently, the CM safety committee recommends the withdrawal of 
nephrotoxic drugs before CM administration [85].
6.1.5 N-Acetylcysteine (NAC)
NAC gives protection against CIN by improving the body’s antioxidant abilities 
[88]. In vitro, NAC does this efficiently by scavenging hypochlorous acid as well 
as reacting with hydroxyl radicals [89]. In vivo due to its extensive degradation, it 
is likely that any antioxidant effect it exerts would be indirect, most probably by 
inducing glutathione synthesis. Different studies have suggested that NAC guards 
against glutathione depletion [90, 91] and elevates renal glutathione levels [92]; the 
latter has been demonstrated to result in the reduction of renal injury in ischemia 
reperfusion models [93, 94] and recently in CIN [95, 96]. Glutathione cannot enter 
the cell; instead, it must be formed inside the cell from glycine, glutamate, and 
cysteine [97]. Cysteine offers the active HS group which is crucial for the glutathi-
one synthesis and thus is the rate-limiting factor in this process. NAC after deacyla-
tion produces cysteine that passes to the renal cells and serves as a precursor for 
glutathione synthesis. It can also produce vasodilator effects [98]. By ameliorating 
contrast-induced vasoconstriction, NAC can produce its nephron-protective role 
[99]. Increase in the medullary blood flow with NAC has also been demonstrated 
[100, 101]. The first clinical use of NAC for CIN was reported by Tepel et al. [83]. 
Eighty-three patients who had chronic renal impairment were randomly planned 
either to take oral NAC (600 mg twice daily) and 0.45% saline intravenously, before 
and after administration of the CM, or to receive placebo and saline. NAC-receiving 
patients had lower incidence of CIN. Since then numerous studies have assessed the 
role of NAC against CIN. Those studies have been done mainly in patients undergo-
ing coronary angiography [102]. Some 17 meta-analyses have been published as 
regards this subject [76, 86, 87, 103–116], 10 that approve its use (most of which 
were published early on). Most of these meta-analyses reported vast heterogeneity 
that makes it difficult to make clinical treatment recommendations relying on the 
provided data. Recently, results of the largest multicenter RCT of 2308 patients 
called “Acetylcysteine for Contrast-Induced Nephropathy Trial” (ACT) have been 
published [36]. It randomized patients in 46 centers in Brazil, to take 1200 mg 
of oral NAC or placebo twice daily for 2 doses before and after the procedure. 
Intravenous hydration with normal saline, 1 mL/kg/h, from 6–12 h before to 6–12 h 
after angiography, was strongly recommended. NAC was not able to significantly 
reduce the incidence of CIN (12.7% in the NAC group and 12.7% in the control 
group, p = 0.97) [117].
6.1.6 Ascorbic acid
Ascorbic acid serves as an antioxidant [118]. It does this via reacting with most 
biologically relevant free radicals and oxidants such as superoxide ions and hydroxyl 
ion [119]. It donates an electron to devastating oxidizing radicals [120]; this one-
electron oxidation leads to the formation of AHˉ the ascorbyl radical also called 
semidehydroascorbic acid [121]. Consequently, the reactive free radical is reduced 
[122]. Ascorbic acid has been reported to result in vasodilatation in coronary [123] 
and brachial arteries [124]. Thus, vitamin C can have favorable effects on vascular 
dilatation, through its antioxidant actions on nitric oxide, but these findings are 
not consistent [125]. Through which pathway vitamin C may offer nephron protec-
tion against CIN is still currently uninvestigated. The first clinical use of ascorbic 
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acid for CIN prevention was reported by Spargias and his colleagues [116]. Two 
hundred and thirty-one patients were summoned and randomized to obtain either 
3 g of ascorbic acid supplied in chewable tablets or placebo at least 2 h prior to the 
beginning of the required procedure. This was followed by 2 g of ascorbic acid or 
placebo the night and the morning post-procedure. Intravenous hydration with 
normal saline at a rate of 50–125 mL/h was started in every patient till at least 6 h 
post-procedure. Incidence of CIN was less in ascorbic acid group (9%) and 20% in 
control group (p = 0.02). A considerable change in the antioxidant state was noticed 
in the group treated with ascorbic acid. Since then various RCTs have been per-
formed [126, 127]. Pooled analysis of these trials assumed that patients who receive 
ascorbic acid have 33% less risk of CIN in comparison with patients receiving 
placebo or alternative pharmacological therapy (RR: 0.67 (95% CI: 0.46–0.96), p = 
0.03) [100]. This indicates that ascorbic acid provides effective nephron protection 
in the face of CIN and may form a part of efficient prophylactic pharmacological 
regimens. However, the utilization of ascorbic acid has not yet been recommended 
by the contrast media safety committee.
6.2 Statins
Statins maintain nitric oxide formation, lower oxidative stress, and beneficially 
affect the endothelial function [101]. In one retrospective study of more than 1,000 
patients with renal impairment undergoing coronary angiography, the risk of CIN 
was markedly decreased in patients who are receiving a statin before the procedure 
[128]. Another study of more than 29,000 patient recorded in a percutaneous 
cardiac intervention registry demonstrated that patients who received statins before 
the procedure had both a lower CIN incidence (p < 0.0001) and nephropathy that 
required dialysis (p < 0.03) [181]. Further studies looking into the benefit from 
statins are warranted [129].
6.2.1 High-dose versus low-dose statins
High-dose statin therapy may be theoretically more efficacious regarding CIN 
prevention as a result of acute suppression of inflammatory chemokines [130]. 
Xie and his colleagues investigated the potency of high-dose statins (simvastatin 
80mg, atorvastatin 40 and 80 mg) compared with low-dose statins (simvastatin 
20 mg, atorvastatin 10 and 20mg) and revealed that high-dose statins lowered the 
incidence of CIN [131]. These results were backed up by a recent meta-analysis 
which showed that high-dose statins (atorvastatin 80 mg, simvastatin 80 mg) in 
comparison with low-dose statins (atorvastatin 10 and 20 mg, simvastatin 20 mg) 
in patients having acute coronary syndromes resulted in a relative risk ratio for CIN 
of 0.46 (4.5 vs 10.2%, p = 0.004); however, it was not of considerable significance 
among patients performing elective procedures [132]. However, high-dose statins 
are guideline recommended medications to lower the risk of CIN.
6.2.2 Theophylline
Adenosine has been implicated to be a responsible factor for mediating 
CM-enhanced renal vasoconstriction [133–135]: hence the use of adenosine antago-
nists appears logical [136]. Theophylline and aminophylline have been often used 
to measure their efficacy as adenosine receptor antagonists in guarding against 
contrast-induced acute kidney injury (CI-AKI). Various randomized trials have 
used theophylline [20, 137, 138]. A meta-analysis of those studies guided to the fact 
that theophylline considerably lowers the risk of CIN (RR: 0.48; 95% CI: 0.26–0.89; 
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p = 0.02). There was moderate heterogeneity that suggests cautious interpretation 
of these results. Furthermore, patients with baseline renal insufficiency did not 
show any benefit from theophylline.
6.2.3 Allopurinol
This drug is a xanthine oxidase inhibitor which may hamper the fall in the GFR 
following CM exposure by limiting oxygen free radical production, inhibiting 
adenine nucleotide degradation, and limiting the vasodilator reaction to intrarenal 
adenosine. A trial that included 159 patients randomized patients performing 
coronary angiography procedures to allopurinol (300 mg orally) with hydration 
or hydration alone, showed that allopurinol can guard against CIN in high-risk 
patients receiving CM [139]. However, these effects of allopurinol in the prevention 
of CIN need further larger studies.
6.2.4 Dopamine
Dopamine (in a renal dose 0.5–2.5 μg/kg/min) has a vasodilator action on the 
renal vasculature and has an ability to increase renal blood flow and GFR with a 
potential benefit in the prevention of CIN. Trials with positive results were small, 
not randomized and with questionable endpoints [140]. On the contrary, negative 
trials were large, randomized, controlled, and with adequate statistical power [141]. 
Thus, the usage of dopamine in guarding against CIN is no longer recommended.
6.2.5 Targeted renal therapy
A suggested theory for failure of various drugs used for kidney protection is that 
systemically administered drugs may not achieve adequate drug level in the renal 
vasculature in order to be successful regarding the prevention of CIN. This has led 
to the technique of direct infusion of a drug in a selective manner into the kidneys 
via the renal arteries, which is known as targeted renal therapy (TRT). This should 
have the ability of decreasing the systemic side effects of that drug. Fenoldopam is 
a dopamine-1 agonist that acts as a vasodilator and thus has a potential to attenu-
ate the vasoconstriction induced by CM in the renal vessels. Although it was not 
possible to demonstrate its benefit in reducing the incidence of CIN [142], it was 
observed that a large number of patients could not tolerate low doses of fenoldo-
pam as a result of drug-induced hypotension, which is itself a risk predictor of 
CIN. Employing TRT, selective bilateral renal artery catheterization may be per-
formed for localized drug delivery. In a pilot study on patients undergoing endovas-
cular aneurysm repair, Benephit PV Infusion System (Flow Medica, Inc., Fremont, 
CA, USA) was used for selective catheterization of both renal arteries through 
brachial artery puncture. There was no episode of hypotension, thus every patient 
received fenoldopam at a rate of 0.4 μg/kg/min for the duration of the aneurysm 
repair [143]. If the pigtail catheter is inserted in the aorta just over the level of the 
renal artery avoiding selective catheterization, this appears to be a simple way but 
would lead to considerable systemic drug effects as a result of infusion of the drug 
into the systemic circulation [143]. The safety and performance of TRT were also 
assessed by retrospective analysis of 285 patients who received fenoldopam via 
TRT, as a part of “The Benephit System Renal Infusion Therapy (Be-RITe)” registry 
[144]. Benephit Infusion System (Flow Medica, Inc., Fremont, CA, USA) was used. 
Bilateral renal artery cannulation achieved success in 94.2%, with a mean cannula-
tion time of 2 min. Incidence of CIN was 71% less than predicted, with the greatest 
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benefit in patients with highest risk of CIN. Prospective studies and RCTs are 
therefore required in order to assess real ability of this technique.
6.2.6 Ischemic preconditioning
Ischemic preconditioning includes exposure to short episodes of ischemia fol-
lowed by reperfusion to make the target organ prepared against the main ischemic 
insult. If the site of generation of these short episodes of ischemic reperfusion is 
remote from the site of target organ, it is called remote ischemic preconditioning. 
This technique has been used with only variable success in offering myocardial and 
renal protection in cardiovascular medicine [145–151]. Results of an RCT propose 
usefulness from remote ischemic preconditioning in preventing CIN [152]. The 
likely usefulness may arise from its capability to attenuate the CM-induced ischemia 
reperfusion injury. Recently, ischemic preconditioning has lost its credibility as it 
was unable to translate successful results in laboratories into clinical practice [153].
7. Sequelae
Patients who develop CIN have greater complications, a worse prognosis, more 
serious long-term outcomes, and longer duration of hospital stay, which result in 
elevated medical costs [154, 155]. Less than 0.5–2% of patients who develop CIN 
require dialysis [156]. Those requiring dialysis are more likely to exhibit serious 
short- and long-term outcomes. Nearly 30% of those patients experience chronic 
renal impairment [154]. CIN may also be linked to an increased mortality which is 
independent of other risk factors [157]. Hospital death rates in such patients have 
been reported as 36% and the 2-year survival rate as only 19% [158, 159]. Levy et al. 
compared 181 inpatients that developed CIN with matched control patients who 
did not develop it; both groups underwent contrast-related procedures [156]. The 
mortality rate in the control group was 7%, compared to 34% in the CIN group. In 
another study of 7230 patients who underwent percutaneous coronary interven-
tions, patients who developed CIN had more common myocardial infarctions, 
more hospital stays, and higher 1-year mortality rates compared to those without 
CIN. CIN patients are more likely to have target vessel revascularization after 1 
year, bypass surgery, bleeding which mandates transfusion, and various vascular 
complications [160]. Patients who undergo a primary percutaneous intervention for 
acute myocardial infarction and the procedure complicates by CIN were reported to 
be significantly more likely to have major complications within hospital admission 
such as acute pulmonary edema, the need for pacemaker insertion, cardiogenic 
shock, and respiratory failure [160]. Patients with renal insufficiency are at more 
significant risk of developing atherosclerosis [19]. Actually, following a contrast 
procedure, a rise in serum creatinine is a more significant indicator of late mortality 
compared to an elevated creatine kinase-MB isoenzyme [160].
8. Conclusion
Contrast-induced nephropathy is a not an uncommon sequela of coronary 
angioplasty. It can lead to increased morbidity and mortality. One should be aware 
of the risk factors that increase its incidence and thus limit the amount of contrast 
so as to avoid such a deleterious complication. Prevention is better than treatment in 
this case.
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